Pembrolizumab 200 mg Q3W

DRUG3 trials

Sponsors

Baptist Health South Florida, CatalYm GmbH, Gruppo Oncologico Italiano di Ricerca Clinica

Conditions

Adult Solid TumorMetastatic Non-Squamous Non-Small Cell Lung CancerSolid Tumor, AdultccRCC

Phase 2

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

CompletedNCT03274661

Baptist Health South FloridaSolid Tumor, Adult

Start: 2017-11-03End: 2022-03-19Updated: 2023-10-19

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

RecruitingNCT07098988

CatalYm GmbHAdult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer

Start: 2025-08-01End: 2031-03-31Target: 107Updated: 2026-02-27

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Not yet recruitingNCT07460206

Gruppo Oncologico Italiano di Ricerca ClinicaccRCC

Start: 2026-08-01End: 2031-12-01Target: 108Updated: 2026-03-10

Related Papers

Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).

Journal of Clinical Oncology2019-05-20

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Journal of Clinical Oncology2018-05-20